ArticleLeukemia2022

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1.

Warren Fiskus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.